Literature DB >> 6097662

Secondary thyroid neoplasms in pediatric cancer patients: increased risk with improved survival.

D Vane, D R King, E T Boles.   

Abstract

Between 1973 and 1983, eight children who had undergone successful multimodal management of malignant tumors developed secondary thyroid neoplasms. The primary tumors were acute lymphocytic leukemia in three, Wilms' tumor in two, and Hodgkin's disease, rhabdomyosarcoma, and ganglioneuroblastoma in one each. During this period, 174 long-term survivors with these five diagnoses were enrolled in our tumor registry, yielding a 4.6% incidence of secondary thyroid neoplasms. All eight patients received both radiation and chemotherapy. The mean radiation dose was 2,700 r with a calculated thyroid dose of 2,140 r (range, 5 to 4,200 r). Age of diagnosis of the primary tumors ranged from 1 to 8 2/12 years (mean, 5 years), and the latent period between treatment and development of the thyroid lesions averaged 6 1/2 years. Thyroid neoplasms presented at an average age of 11 4/12 years. Five patients developed solitary adenomas, one presented with multiple adenomas, and two had follicular carcinoma with regional lymph node metastases. Although thyroid neoplasms are rare in childhood, clinically apparent thyroid tumors have been observed in up to 2.5% of children following radiation exposure (mean follow-up, 24 years). The reported latent period before the development of thyroid neoplasms in irradiated patients is at least 10 years, with the peak incidence occurring 20 to 25 years after exposure. This study documents a 4.6% incidence of subsequent thyroid neoplasms in pediatric cancer patients within a relatively short follow-up period (mean, 11 years). These thyroid tumors occurred at an earlier age (mean, 11.5 years) and with a shorter latent period (mean, 6.5 years) than would be predicted from previous studies.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1984        PMID: 6097662     DOI: 10.1016/s0022-3468(84)80384-x

Source DB:  PubMed          Journal:  J Pediatr Surg        ISSN: 0022-3468            Impact factor:   2.545


  7 in total

1.  DNA fragile site breakage as a measure of chemical exposure and predictor of individual susceptibility to form oncogenic rearrangements.

Authors:  Christine E Lehman; Laura W Dillon; Yuri E Nikiforov; Yuh-Hwa Wang
Journal:  Carcinogenesis       Date:  2017-03-01       Impact factor: 4.944

2.  Patients exposed to diagnostic head and neck radiation for the management of shunted hydrocephalus have a significant risk of developing thyroid nodules.

Authors:  Jennifer H Aldrink; Brent Adler; Jesse Haines; Daniel Watkins; Mika Matthews; Lacey Lubeley; Wei Wang; Denis R King
Journal:  Pediatr Surg Int       Date:  2016-04-15       Impact factor: 1.827

Review 3.  Targeted therapy aimed at cancer stem cells: Wilms' tumor as an example.

Authors:  Rachel Shukrun; Naomi Pode Shakked; Benjamin Dekel
Journal:  Pediatr Nephrol       Date:  2013-06-13       Impact factor: 3.714

4.  The role of fragile sites in sporadic papillary thyroid carcinoma.

Authors:  Laura W Dillon; Christine E Lehman; Yuh-Hwa Wang
Journal:  J Thyroid Res       Date:  2012-06-11

5.  The isolation and characterization of renal cancer initiating cells from human Wilms' tumour xenografts unveils new therapeutic targets.

Authors:  Naomi Pode-Shakked; Rachel Shukrun; Michal Mark-Danieli; Peter Tsvetkov; Sarit Bahar; Sara Pri-Chen; Ronald S Goldstein; Eithan Rom-Gross; Yoram Mor; Edward Fridman; Karen Meir; Amos Simon; Marcus Magister; Naftali Kaminski; Victor S Goldmacher; Orit Harari-Steinberg; Benjamin Dekel
Journal:  EMBO Mol Med       Date:  2012-12-13       Impact factor: 12.137

6.  DNA topoisomerases participate in fragility of the oncogene RET.

Authors:  Laura W Dillon; Levi C T Pierce; Christine E Lehman; Yuri E Nikiforov; Yuh-Hwa Wang
Journal:  PLoS One       Date:  2013-09-11       Impact factor: 3.240

Review 7.  Broken by the Cut: A Journey into the Role of Topoisomerase II in DNA Fragility.

Authors:  Naomi D Atkin; Heather M Raimer; Yuh-Hwa Wang
Journal:  Genes (Basel)       Date:  2019-10-12       Impact factor: 4.141

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.